[{"orgOrder":0,"company":"Vaneltix Pharma","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Lidocaine","moa":"||NaV channel-alpha-subunit","graph1":"Urology","graph2":"Phase II","graph3":"Vaneltix Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intravesical Pre-Filled Injection","sponsorNew":"Vaneltix Pharma \/ Hyloris Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Vaneltix Pharma \/ Hyloris Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Vaneltix Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : Under the terms of the agreement, Vaneltix will be responsible for the further development, manufacturing, regulatory affairs and commercialisation of AlenuraTM in collaboration with Hyloris.

                          Product Name : Alenura

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          December 17, 2021

                          Lead Product(s) : Lidocaine,Heparin Sodium

                          Therapeutic Area : Urology

                          Highest Development Status : Phase II

                          Sponsor : Hyloris Pharmaceuticals

                          Deal Size : $6.7 million

                          Deal Type : Collaboration

                          blank